{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:25:15Z","timestamp":1792182315980,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.taap.2021.115555","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T11:50:04Z","timestamp":1619437804000},"page":"115555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Evaluating the protective effects of individual or combined ginsenoside compound K and the downregulation of soluble epoxide hydrolase expression against sodium valproate-induced liver cell damage"],"prefix":"10.1016","volume":"422","author":[{"given":"Luping","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangchang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2021.115555_bb0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.etap.2018.05.021","article-title":"In vivo investigation on the chronic hepatotoxicity induced by sertraline","volume":"61","author":"Almansour","year":"2018","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.taap.2021.115555_bb0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3389\/fphar.2017.00965","article-title":"Single- and multiple-dose trials to determine the pharmacokinetics, safety, tolerability, and sex effect of oral ginsenoside compound K in healthy Chinese volunteers","volume":"8","author":"Chen","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2021.115555_bb0015","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3389\/fphar.2017.00636","article-title":"Food and sex-related impacts on the pharmacokinetics of a single-dose of Ginsenoside compound K in healthy subjects","volume":"8","author":"Chen","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.taap.2021.115555_bb0020","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1007\/s11033-019-04988-0","article-title":"Ginsenoside compound K ameliorates Alzheimer\u2019s disease in HT22 cells by adjusting energy metabolism","volume":"46","author":"Chen","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.taap.2021.115555_bb0025","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.taap.2018.06.025","article-title":"Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner","volume":"355","author":"Cizkova","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.taap.2021.115555_bb0030","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1073\/pnas.0437829100","article-title":"The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase","volume":"100","author":"Cronin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.taap.2021.115555_bb0035","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00204-014-1371-y","article-title":"The role of epoxide hydrolases in health and disease","volume":"88","author":"El-Sherbeni","year":"2014","journal-title":"Arch. Toxicol."},{"issue":"1\u20132","key":"10.1016\/j.taap.2021.115555_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-2797(00)00197-6","article-title":"Epoxide hydrolases: biochemistry and molecular biology","volume":"129","author":"Fretland","year":"2000","journal-title":"Chem. Biol. Interact."},{"issue":"2","key":"10.1016\/j.taap.2021.115555_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2013.05.008","article-title":"Soluble epoxide hydrolase: gene structure, expression and deletion","volume":"526","author":"Harris","year":"2013","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.taap.2021.115555_bb0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/1753-0407.12358","article-title":"Soluble epoxide hydrolase: a potential target for metabolic diseases","volume":"8","author":"He","year":"2016","journal-title":"J Diabetes"},{"issue":"6","key":"10.1016\/j.taap.2021.115555_bb0055","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.bbadis.2017.02.004","article-title":"Endothelial Nox4-based NADPH oxidase regulates atherosclerosis via soluble epoxide hydrolase","volume":"1863","author":"Hu","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"8","key":"10.1016\/j.taap.2021.115555_bb0060","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/15376516.2013.821567","article-title":"Toxicity of valproic acid in isolated rat liver mitochondria","volume":"23","author":"Jafarian","year":"2013","journal-title":"Toxicol. Mech. Methods"},{"issue":"1","key":"10.1016\/j.taap.2021.115555_bb0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s002040050250","article-title":"Tissue specific basal expression of soluble murine epoxide hydrolase and effects of clofibrate on the mRNA levels in extrahepatic tissues and liver","volume":"70","author":"Johansson","year":"1995","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.taap.2021.115555_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tox.2015.03.001","article-title":"Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro cell model","volume":"331","author":"Komulainen","year":"2015","journal-title":"Toxicology"},{"key":"10.1016\/j.taap.2021.115555_bb0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.coph.2014.12.006","article-title":"Hypertension and new treatment approaches targeting the sympathetic nervous system","volume":"21","author":"Laffin","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.taap.2021.115555_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.29806","article-title":"Epoxyeicosatrienoic acids inhibit the activation of NLRP3 inflammasome in murine macrophages","author":"Luo","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.taap.2021.115555_bb0085","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jcmgh.2020.10.002","article-title":"Soluble epoxide hydrolase hepatic deficiency ameliorates alcohol-associated liver disease","volume":"11","author":"Mello","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.taap.2021.115555_bb0090","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/jcbfm.2015.159","article-title":"Peroxisomal translocation of soluble epoxide hydrolase protects against ischemic stroke injury","volume":"35","author":"Nelson","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"5","key":"10.1016\/j.taap.2021.115555_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0152742","article-title":"Disrupting dimerization Translocates soluble epoxide hydrolase to peroxisomes","volume":"11","author":"Nelson","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.taap.2021.115555_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030484","article-title":"Ginsenoside compound K induces adult hippocampal proliferation and survival of newly generated cells in young and elderly mice","volume":"10","author":"Oh","year":"2020","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.taap.2021.115555_bb0105","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1161\/CIRCRESAHA.116.303603","article-title":"New approaches in the treatment of hypertension","volume":"116","author":"Oparil","year":"2015","journal-title":"Circ. Res."},{"issue":"7","key":"10.1016\/j.taap.2021.115555_bb0110","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1631\/jzus.B1400346","article-title":"Chlorogenic acid prevents acetaminophen-induced liver injury: the involvement of CYP450 metabolic enzymes and some antioxidant signals","volume":"16","author":"Pang","year":"2015","journal-title":"J Zhejiang Univ Sci B"},{"issue":"1","key":"10.1016\/j.taap.2021.115555_bb0115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1096\/fj.201900927RR","article-title":"Butyrate prevents valproate-induced liver injury: in vitro and in vivo evidence","volume":"34","author":"Pirozzi","year":"2020","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.taap.2021.115555_bb0120","first-page":"75","article-title":"Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives","volume":"4","author":"Ramachandran","year":"2018","journal-title":"J Clin Transl Res"},{"issue":"1","key":"10.1016\/j.taap.2021.115555_bb0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0163-7827(03)00049-3","article-title":"Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function","volume":"43","author":"Spector","year":"2004","journal-title":"Prog. Lipid Res."},{"issue":"4","key":"10.1016\/j.taap.2021.115555_bb0130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.bbrc.2019.12.131","article-title":"PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice","volume":"523","author":"Sun","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.taap.2021.115555_bb0135","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1038\/s41598-018-23504-1","article-title":"Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia","volume":"8","author":"Tu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2021.115555_bb0140","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2017.09.013","article-title":"Antiepileptic drugs and liver disease","volume":"77","author":"Vidaurre","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.taap.2021.115555_bb0145","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","article-title":"Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases","volume":"180","author":"Wagner","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.taap.2021.115555_bb0150","article-title":"Inhibition of soluble epoxide hydrolase by T-TUCB ameliorated liver injury in a chronic-binge ethanol administration mouse model","volume":"32","author":"Warner","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.taap.2021.115555_bb0155","first-page":"32","article-title":"Inhibition of soluble epoxide hydrolase by t-TUCB ameliorated liver injury in a chronic-binge ethanol administration mouse model","author":"Warner","year":"2018","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.taap.2021.115555_bb0160","first-page":"816A","article-title":"Imbalance of epoxide and diol lipid mediators in alcoholic liver disease:effects of soluble epoxide hydrolase inhibition in experimental mice","volume":"68","author":"Warner","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.taap.2021.115555_bb0165","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.fitote.2014.11.019","article-title":"A review of biotransformation and pharmacology of ginsenoside compound K","volume":"100","author":"Yang","year":"2015","journal-title":"Fitoterapia"},{"issue":"1","key":"10.1016\/j.taap.2021.115555_bb0170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12031-018-1210-3","article-title":"Ginsenoside compound K regulates amyloid beta via the Nrf2\/Keap1 signaling pathway in mice with scopolamine Hydrobromide-induced memory impairments","volume":"67","author":"Yang","year":"2019","journal-title":"J. Mol. Neurosci."},{"issue":"11","key":"10.1016\/j.taap.2021.115555_bb0175","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.7150\/thno.43108","article-title":"A COX-2\/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.taap.2021.115555_bb0180","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3389\/fphar.2018.01020","article-title":"The effects of ginsenoside compound K against epilepsy by enhancing the gamma-aminobutyric acid signaling pathway","volume":"9","author":"Zeng","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2021.115555_bb0185","doi-asserted-by":"crossref","first-page":"109907","DOI":"10.1016\/j.biopha.2020.109907","article-title":"A COX-2\/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress","volume":"126","author":"Zhang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.taap.2021.115555_bb0190","doi-asserted-by":"crossref","first-page":"114829","DOI":"10.1016\/j.taap.2019.114829","article-title":"Ginsenoside compound K alleviates sodium valproate-induced hepatotoxicity in rats via antioxidant effect, regulation of peroxisome pathway and iron homeostasis","volume":"386","author":"Zhou","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.taap.2021.115555_bb0195","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jphs.2019.01.013","article-title":"Ginsenoside compound K attenuates cognitive deficits in vascular dementia rats by reducing the Abeta deposition","volume":"139","author":"Zong","year":"2019","journal-title":"J. Pharmacol. Sci."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X21001629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X21001629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:54:43Z","timestamp":1758574483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X21001629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":39,"alternative-id":["S0041008X21001629"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2021.115555","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the protective effects of individual or combined ginsenoside compound K and the downregulation of soluble epoxide hydrolase expression against sodium valproate-induced liver cell damage","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2021.115555","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115555"}}